Autres langues TME Pharma N.V.

Actions

ALTME

NL0015000YE1

Temps réel Euronext Paris Autres places de cotation 17:01:02 10/06/2024			Varia. 5j.	Varia. 1 janv.
0,226 ^EUR	-1,74 %		-9,42 %	-1,74 %

26/04	En Direct des Marchés : TotalEnergies, Saint-Gobain, Safran, Airbus, Unibail, BHP, Microsoft, Alphabet...
25/04	TME Pharma N.V. publie ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

TME Pharma Announces Convocation of the 2024 Annual General Meeting of Shareholders	27/05
TME Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	25/04
TME Pharma Publishes 2023 Financial Results and Provides Operating Update	25/04
TME PHARMA ANNOUNCES 33% OF PATIENTS RECEIVING NOX-A12 IN COMBINATION WITH BEVACIZUMAB AND RADIOTHERAPY ACHIEVE TWO-YEAR SURVIVAL IN GLORIA PHASE 1/2 TRIAL IN BRAIN CANCER	24/04
TME Pharma Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two‑Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer	23/04
TME Pharma N.V. Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two-Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer	23/04
TME Pharma : désignation Fast Track dans le glioblastome	03/04
Bolsa de Madrid: Después de Semana Santa, algo va mal	03/04
TME Pharma N : Inside Information / Other news releases	02/04
TME Pharma Receives US FDA Fast Track Designation for Lead Asset NOX-A12 in Brain Cancer	02/04
TME Pharma N.V. Receives US FDA Fast Track Designation for Lead Asset NOX-A12 in Brain Cancer	02/04
TME Pharma N : receives US FDA Fast Track designation for lead asset NOX-A12 in brain cancer	02/04
TME PHARMA : Invest Securities ajuste légèrement sa cible	02/04
TME Pharma Provides Results of First Exercise of Warrants Z	28/03
TME Pharma : feu vert de la FDA pour lancer un essai de ph.II	05/03
TME Pharma N.V. Announces FDA Clearance of Investigational New Drug Application for Nox-A12 Phase 2 Trial in Brain Cancer	05/03
TME PHARMA PROVIDES RESULTS OF FINAL EXERCISE OF WARRANTS Y: ADDITIONAL EUR854K RAISED AND EXTENSION OF CASH RUNWAY FROM MAY INTO JULY 2024	26/02
TME Pharma : fin du programme d'obligations convertibles	09/02
TME Pharma Raises EUR1.5 Million to Buy Back Convertible Bonds	09/02
TME Pharma N.V. announced that it expects to receive ?1.479999 million in funding	09/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues TME Pharma N.V.

Actions

ALTME

NL0015000YE1

Autres langues

Filtres